281 related articles for article (PubMed ID: 29569115)
1. [Systemic immune checkpoint inhibition : A promising treatment for urological tumors?].
Roos FC; Becker C; Stope MB; Tsaur I;
Urologe A; 2018 May; 57(5):583-590. PubMed ID: 29569115
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
3. Present status and future perspective of peptide-based vaccine therapy for urological cancer.
Obara W; Kanehira M; Katagiri T; Kato R; Kato Y; Takata R
Cancer Sci; 2018 Mar; 109(3):550-559. PubMed ID: 29345737
[TBL] [Abstract][Full Text] [Related]
4. [Immunooncology in Urologic Cancers: Current Status].
Grimm MO
Aktuelle Urol; 2016 Sep; 47(5):374-7. PubMed ID: 27680188
[TBL] [Abstract][Full Text] [Related]
5. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
6. Current Role of Checkpoint Inhibitors in Urologic Cancers.
Attalla K; Sfakianos JP; Galsky MD
Cancer Treat Res; 2018; 175():241-258. PubMed ID: 30168125
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
8. [Precision oncology options in urological cancers].
Franz A; Plage H; Fendler A; Schlomm T; Kornienko K
Urologie; 2023 Jul; 62(7):696-704. PubMed ID: 37294331
[TBL] [Abstract][Full Text] [Related]
9. Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma.
Weiss J; Notohamiprodjo M; Bedke J; Nikolaou K; Kaufmann S
Curr Opin Urol; 2018 Jan; 28(1):35-41. PubMed ID: 29083998
[TBL] [Abstract][Full Text] [Related]
10. Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy.
Bergerot CD; Bergerot PG; Philip EJ; Hsu JA; Dizman N; Vaishampayan U; Dorff T; Pal SK
J Immunother Cancer; 2019 Mar; 7(1):71. PubMed ID: 30867071
[TBL] [Abstract][Full Text] [Related]
11. [Side effects of immune checkpoint inhibitor treatment of urological tumors].
Grimm MO; Gottschlich T; Ali N; Foller S; Leucht K
Urologe A; 2021 Jun; 60(6):803-815. PubMed ID: 34100956
[TBL] [Abstract][Full Text] [Related]
12. Landscape of Immunotherapy in Genitourinary Malignancies.
Ravindranathan D; Alhalabi O; Rafei H; Shah AY; Bilen MA
Adv Exp Med Biol; 2021; 1342():143-192. PubMed ID: 34972965
[TBL] [Abstract][Full Text] [Related]
13. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019.
Grimm MO; Bex A; De Santis M; Ljungberg B; Catto JWF; Rouprêt M; Hussain SA; Bellmunt J; Powles T; Wirth M; Van Poppel H
Eur Urol; 2019 Sep; 76(3):368-380. PubMed ID: 31235192
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract][Full Text] [Related]
15. Use of immunotherapy in clinical management of genitourinary cancers - a review.
Mar N; Uchio E; Kalebasty AR
Cancer Treat Res Commun; 2022; 31():100564. PubMed ID: 35472699
[TBL] [Abstract][Full Text] [Related]
16. [Influence of immunomodulators on urological imaging].
Peisen F; Thaiss W; Tietze N; Rausch S; Amend B; Nikolaou K; Bedke J; Stenzl A; Kaufmann S
Urologe A; 2019 Dec; 58(12):1451-1460. PubMed ID: 31705144
[TBL] [Abstract][Full Text] [Related]
17. Fecal microbiota transplantation for immunotherapy-resistant urological tumors: Is it time? An update of the recent literature.
Mjaess G; Karam A; Aoun F; Albisinni S; Roumeguère T
Cancer; 2022 Jan; 128(1):14-19. PubMed ID: 34494666
[No Abstract] [Full Text] [Related]
18. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Flippot R; Escudier B; Albiges L
Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in medical therapy for metastatic urothelial cancer.
Yuasa T; Urakami S; Yonese J
Int J Clin Oncol; 2018 Aug; 23(4):599-607. PubMed ID: 29556919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
